SCHEMBL18325342

SCHEMBL18325342

Cc1ccc(-c2cc(-c3ccccn3)cc(-c3nc(-c4ccc(-c5ccccc5)cc4)nc(-c4ccc(-c5ccccc5)cc4)n3)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
TP53 P04637 3/20 0.50
PKM P14618 3/20 0.50
GRM5 P41594 3/20 0.47
KDM4E B2RXH2 7/20 0.46
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
RAB9A P51151 3/20 0.46
HPGD P15428 3/20 0.46
HSD17B10 Q99714 2/20 0.46
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.46
TSHR P16473 1/20 0.46
KLF5 Q13887 1/20 0.46
HIF1A Q16665 1/20 0.45
TDP1 Q9NUW8 2/20 0.44
NPC1 O15118 4/20 0.44
ADORA3 P0DMS8 1/20 0.44
ADORA2A P29274 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18325245 1.00 MEN1 (0.50) MEN1KMT2ATP53PKMGRM5
SCHEMBL18325369 1.00 MEN1 (0.50) MEN1KMT2ATP53PKMGRM5
SCHEMBL18325195 1.00 MEN1 (0.50) MEN1KMT2ATP53PKMGRM5
SCHEMBL18325351 0.97 MEN1 (0.50) MEN1KMT2ATP53PKMGRM5
SCHEMBL1371139 0.97 MEN1 (0.50) MEN1KMT2ATP53PKMGRM5
SCHEMBL17932492 0.97 MEN1 (0.50) MEN1KMT2ATP53PKMGRM5
SCHEMBL1371603 0.97 MEN1 (0.50) MEN1KMT2ATP53PKMGRM5
SCHEMBL18325217 0.97 MEN1 (0.50) MEN1KMT2ATP53PKMGRM5
SCHEMBL17932494 0.94 GRM5 (0.51) MEN1KMT2ATP53PKMGRM5
SCHEMBL18325363 0.94 GRM5 (0.51) MEN1KMT2ATP53PKMGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9812652-B2 Cyclic azine compound having adamantyl group, production method, and organic electroluminescent device containing it as constituent component TOSOH CORPORATION (JP) 2017-11-07 US disclosed
US-20160372678-A1 CYCLIC AZINE COMPOUND HAVING ADAMANTYL GROUP, PRODUCTION METHOD, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING IT AS CONSTITUENT COMPONENT TOSOH CORPORATION (JP) 2016-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160372678-A1 CYCLIC AZINE COMPOUND HAVING ADAMANTYL GROUP, PRODUCTION METHOD, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING IT AS CONSTITUENT COMPONENT CHRM1, AFF1, AZI2 MEN1 210/4885KMT2A 3381/4885TP53 4476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.